Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis

Bone Marrow Transplant. 2015 Apr;50(4):610-2. doi: 10.1038/bmt.2014.318. Epub 2015 Jan 26.

Authors

B Dhakal¹, A D'Souza¹, C Arce-Lara¹, M Pasquini¹, W Saber¹, F Falvo¹, J Esselman¹, K Zellner¹, T Fenske¹, P N Hari¹, M Hamadani¹

Affiliation

¹ Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

PMID: 25621807
DOI: 10.1038/bmt.2014.318

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Amyloidosis* / economics
Amyloidosis* / therapy
Benzylamines
Costs and Cost Analysis
Cyclams
Female
Granulocyte Colony-Stimulating Factor* / administration & dosage
Granulocyte Colony-Stimulating Factor* / economics
Hematopoietic Stem Cell Mobilization / economics*
Hematopoietic Stem Cells*
Heterocyclic Compounds* / administration & dosage
Heterocyclic Compounds* / economics
Humans
Male
Retrospective Studies

Substances

Benzylamines
Cyclams
Heterocyclic Compounds
Granulocyte Colony-Stimulating Factor
plerixafor